On Thursday, Kühne+Nagel announced that it will ensure the worldwide distribution of the Moderna vaccine doses from production sites based in Europe. This includes distribution to markets in Europe, Asia, the Middle East and Africa, as well as parts of the Americas.
“Kuehne+Nagel will use its network of more than 230 operations worldwide to distribute the vaccine via road and air. In Europe alone, the company operates its own fleet of over 200 dedicated pharmaceutical transport vehicles. At all stages of transport and storage, product integrity at the required temperature of -20°C will be maintained,” said the firm on Thursday.
The financial terms of the agreement were not disclosed.
Swiss involvement
Moderna has made good use of Swiss know-how to help manufacture and roll out its vaccine. Quickstat, Kühne+Nagel’s clinical trial logistics subsidiary, has already been part of the supply chain for the Moderna vaccine, having supported the supply logistics for Phase II and Phase III clinical trials in the US.
Swiss pharma company Lonza will produce the Moderna vaccine in Switzerland for non-US markets. It is building three vaccine production lines in the western Swiss town of Visp at a cost of $210 million (CHF191 million) to supply 300 million doses annually for the rest of the world. In parallel, new production lines at Lonza’s site in Portsmouth, New Hampshire, will start making vaccine ingredients exclusively for the US.
On Wednesday, the European Union granted a conditional approval for the Moderna vaccine. However, Switzerland’s medical regulator has not yet given it the green light even though the Alpine nation was one of the early buyers. Switzerland will get 4.5 million doses of the vaccine, enough to vaccinate 2.25 million people if, as expected, two doses are needed per patient.
Should raw milk sales be banned or should consumers decide?
Swiss food regulations do not allow raw milk to be sold for direct consumption. However, a loophole allows 400 raw milk vending machines to do just that.
Real Swiss wages likely to rise in 2025, says UBS bank
This content was published on
Higher wages and falling inflation are likely to boost Swiss purchasing power, which will be dragged back by rising health premiums.
This content was published on
Switzerland has a new tectonic map at a scale of 1:500,000, containing updates to geometry, distribution and nomenclature of the tectonic units.
This content was published on
Swiss artist Daniel Spoerri, known for his artworks using leftover food with dirty cutlery and crockery, has passed away in Vienna at the age of 94.
Climate change tipped to alter Swiss avalanche patterns by 2100
This content was published on
Climate change is expected to result in fewer avalanches overall in Switzerland but to increase the danger of wet snow avalanches by 2100.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19 vaccine: Why we still have a long wait ahead
This content was published on
Countries have started rolling out a Covid-19 vaccine, but it will likely take years to manufacture doses at the scale needed to reach the masses.
Swiss factory rushes to prepare for Moderna Covid-19 vaccine
This content was published on
Workers are racing to set up production lines at the Lonza factory in Visp to be able to start making a vaccine for US firm Moderna later this year.
Why Switzerland’s Moderna Covid-19 vaccine deal is risky
This content was published on
Switzerland’s vaccine order – its first such move – is a sign that it holds little hope for fair distribution of a Covid-19 shot.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.